Table 6.

Episodes in complete follow-up in both groups

Condition	Group 1 (n=89; IgA aB2GPI-Positive)		Group 2 (n=180; IgA aB2GPI-Negative)		P Value
	N	Percent	N	Percent
DGF	25	28.1	26	14.4	0.01
Episodes of AR	12	13.5	17	9.4	0.43
Graft loss	34	38.2	46	25.6	0.05
Causes of graft loss
AR	2	5.9	1	2.2	0.57
Uropathy	0	0	1	2.2	>0.99
Death	13	38.2	28	60.9	0.08
Chronic allograft nephropathy	8	23.5	12	26.1	>0.99
Graft thrombosis	8	23.5	0	0	<0.001
Recurrence of disease.	1	2.9	2	4.3	>0.99
Others	1	2.9	1	2.2	>0.99
Death	17	19.1	30	16.7	0.75
Causes of death
Stroke	2	11.8	4	13.3	>0.99
Heart failure	1	5.9	0	0	0.36
Other cardiovascular disease	2	11.8	2	6.7	0.61
Infection	4	23.5	6	20.0	>0.99
Cancer	1	5.9	4	13.3	0.64
Sudden death	1	5.9	3	10.0	>0.99
Others	6	35.3	9	30.0	0.75
Unknown	0	0	2	6.7	0.53
Other complications
Patients with cancer	12	13.5	22	12.2	0.92
Patients with cardiovascular events	14	15.7	28	15.6	0.89
Immunosuppressant treatment
Calcineurin inhibitors	87	97.8	178	98.8	0.85
CsAa	40	44.9	39	21.7	<0.001
TAC	47	52.8	139	77.2	<0.001
MMF	84	94.4	166	92.2	0.69
Corticosteroids	87	97.8	179	99.4	0.53
Sirolimus	4	4.5	15	8.3	0.37

^aTreatment with CsA is a recipient age-dependent variable.